Human Immunoglobulin E specific for Cavia porcellus allergens (Cav p 1-6) (IgE)

Human IgE antibodies specific for Cav p 1–6 epitopes are a specialized subset of the immunoglobulin E class that mediate allergic sensitivity to the domestic guinea pig (Cavia porcellus). These antibodies are generated by the immune system in response to exposure to guinea pig allergens, which include several lipocalins (Cav p 1, 2, 3, and 6) and serum albumin (Cav p 4) [WHO/IUIS Allergen Nomenclature]. In sensitized individuals, these specific IgE (sIgE) molecules circulate in the blood and bind to high-affinity FcεRI receptors on the surface of mast cells and basophils [Gould and Sutton, Nature 2008]. Upon re-exposure to guinea pig dander or saliva, the allergens cross-link the receptor-bound IgE, triggering the immediate degranulation of these cells and the release of inflammatory mediators such as histamine [Galli and Tsai, Nature Medicine 2012]. This physiological response results in the clinical symptoms of Type I hypersensitivity, including allergic rhinitis, conjunctivitis, and asthma. From a therapeutic perspective, these antibodies are targeted by broad-spectrum anti-IgE agents like omalizumab, which neutralize circulating IgE regardless of its allergen specificity [FDA, Xolair Prescribing Information]. Additionally, measuring the levels of these specific antibodies is essential for component-resolved diagnostics to distinguish between primary sensitization and cross-reactivity with other animal allergens [Hamilton, Human Immunology 2010]. Understanding the specific epitopes of Cav p 1–6 is also critical for the development of targeted immunotherapy aimed at inducing immune tolerance in affected patients.

Other names

Guinea pig specific IgEAnti-Cav p 1-6 IgEsIgE to Cavia porcellusHuman IgE specific for guinea pig allergens

Anti-IgE monoclonal antibodies bind to the Fc region of circulating IgE, specifically the Cε3 domain, preventing its interaction with the high-affinity FcεRI receptor on mast cells and basophils. This sequestration of IgE inhibits the release of inflammatory mediators and leads to the downregulation of FcεRI receptors on the surface of effector cells.